Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

Completed · Phase 2

Conditions studied: Waldenstrom's Macroglobulinemia

In brief

The purpose of this study is to find out if the combination of bortezomib (Velcade), dexamethasone (Decadron) and rituximab (Rituxan) is effective in treating Waldenstrom's macroglobulinemia.

Key facts

Study ID

NCT00250926

Run by

Dana-Farber Cancer Institute

People needed

23

Starts

2005-10-01

Expected to finish

2009-02-01

Last updated by the study team

2016-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinicopathological diagnosis of Waldenstrom's macroglobulinemia (WM)
• No previous therapy for WM
• Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of greater than or equal to 2 times the upper limit of each institution's normal value
• CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed up to 3 months prior to enrollment
• Karnofsky performance status > 60
• Life expectancy > 3 months
• AST (SGOT) < 3 x ULN
• ALT (SGPT) < 3 x ULN
• Total bilirubin < 2 x ULN
• Calculated or measured creatinine clearance > 30mL/minute
• Serum sodium > 130 mmol/L
• Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control
• Male subject agrees to use an acceptable method for contraception for the duration of the study

You may not qualify if…

• Previous therapy for Waldenstrom's macroglobulinemia
• Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
• Hypersensitivity to dexamethasone, boron or mannitol
• Pregnant or breast-feeding women
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.